965 related articles for article (PubMed ID: 29720244)
1. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J
Trials; 2018 May; 19(1):264. PubMed ID: 29720244
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients.
Gudiol C; Arnan M; Aguilar-Guisado M; Royo-Cebrecos C; Sánchez-Ortega I; Montero I; Martín-Gandul C; Laporte-Amargós J; Albasanz-Puig A; Nicolae S; Perayre M; Berbel D; Tebe C; Riera J; Sureda A; Cisneros JM; Carratalà J
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712211
[TBL] [Abstract][Full Text] [Related]
3. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
Winnicki W; Herkner H; Lorenz M; Handisurya A; Kikić Ž; Bielesz B; Schairer B; Reiter T; Eskandary F; Sunder-Plassmann G; Sengoelge G
Kidney Int; 2018 Mar; 93(3):753-760. PubMed ID: 28890326
[TBL] [Abstract][Full Text] [Related]
4. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial.
Tribler S; Brandt CF; Petersen AH; Petersen JH; Fuglsang KA; Staun M; Broebech P; Moser CE; Jeppesen PB
Am J Clin Nutr; 2017 Sep; 106(3):839-848. PubMed ID: 28793993
[No Abstract] [Full Text] [Related]
5. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.
Handrup MM; Møller JK; Schrøder H
Pediatr Blood Cancer; 2013 Aug; 60(8):1292-8. PubMed ID: 23417891
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.
Dümichen MJ; Seeger K; Lode HN; Kühl JS; Ebell W; Degenhardt P; Singer M; Geffers C; Querfeld U
J Hosp Infect; 2012 Apr; 80(4):304-9. PubMed ID: 22342714
[TBL] [Abstract][Full Text] [Related]
7. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Betjes MG; van Agteren M
Nephrol Dial Transplant; 2004 Jun; 19(6):1546-51. PubMed ID: 14993498
[TBL] [Abstract][Full Text] [Related]
8. Cefazolin-gentamicin versus taurolidine-citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial.
Bueloni TNV; Marchi D; Caetano C; de Souza Cavalcante R; Mendes Amaral ML; Ponce D
Int J Infect Dis; 2019 Aug; 85():16-21. PubMed ID: 31102823
[TBL] [Abstract][Full Text] [Related]
9. Taurolidine lock solution for catheter-related bloodstream infections in pediatric patients: A meta-analysis.
Sun Y; Wan G; Liang L
PLoS One; 2020; 15(4):e0231110. PubMed ID: 32255798
[TBL] [Abstract][Full Text] [Related]
10. Use of 2% taurolidine lock solution for treatment and prevention of catheter-related bloodstream infections in neonates: a feasibility study.
Savarese I; Yazami S; De Rose DU; Carkeek K; Campi F; Auriti C; Danhaive O; Piersigilli F
J Hosp Infect; 2024 Jan; 143():76-81. PubMed ID: 37972710
[TBL] [Abstract][Full Text] [Related]
11. Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation.
Jiménez Hernández M; Soriano A; Filella X; Calvo M; Coll E; Rebled JM; Poch E; Graterol F; Compte MT; Maduell F; Fontsere N
J Vasc Access; 2021 May; 22(3):370-379. PubMed ID: 32691665
[TBL] [Abstract][Full Text] [Related]
12. [Taurolidine, an antiseptic for the prevention of central venous catheter-related infections].
Haro C
Rev Chilena Infectol; 2019 Aug; 36(4):414-420. PubMed ID: 31859763
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of taurolidine on the prevention of catheter-related bloodstream infections in patients on home parenteral nutrition.
Al-Amin AH; Sarveswaran J; Wood JM; Burke DA; Donnellan CF
J Vasc Access; 2013; 14(4):379-82. PubMed ID: 23817948
[TBL] [Abstract][Full Text] [Related]
14. Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin.
Handrup MM; Fuursted K; Funch P; Møller JK; Schrøder H
APMIS; 2012 Oct; 120(10):794-801. PubMed ID: 22958287
[TBL] [Abstract][Full Text] [Related]
15. Taurolidine-citrate-heparin catheter lock solution reduces staphylococcal bacteraemia rates in haemodialysis patients.
Murray EC; Deighan C; Geddes C; Thomson PC
QJM; 2014 Dec; 107(12):995-1000. PubMed ID: 24939191
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study.
Al-Ali F; Hamdy AF; Hamad A; Elsayed M; Zafar Iqbal Z; Elsayed A; Ibrahim R; Tolba H; Buanan H; Fawzy A
Nephrol Dial Transplant; 2018 Apr; 33(4):619-626. PubMed ID: 29106676
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients.
Moore CL; Besarab A; Ajluni M; Soi V; Peterson EL; Johnson LE; Zervos MJ; Adams E; Yee J
Clin J Am Soc Nephrol; 2014 Jul; 9(7):1232-9. PubMed ID: 24970874
[TBL] [Abstract][Full Text] [Related]
18. Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial.
Klek S; Szczepanek K; Hermanowicz A; Galas A
JPEN J Parenter Enteral Nutr; 2015 Mar; 39(3):331-5. PubMed ID: 24604029
[TBL] [Abstract][Full Text] [Related]
19. The best solution down the line: an observational study on taurolidine- versus citrate-based lock solutions for central venous catheters in hemodialysis patients.
van Roeden S; van Oevelen M; Abrahams AC; Dekker FW; Rotmans JI; Meijvis SCA;
BMC Nephrol; 2021 Sep; 22(1):308. PubMed ID: 34517829
[TBL] [Abstract][Full Text] [Related]
20. A 2% taurolidine catheter lock solution prevents catheter-related bloodstream infection (CRBSI) and catheter dysfunction in hemodialysis patients.
Neusser MA; Bobe I; Hammermeister A; Wittmann U
Br J Nurs; 2021 Jul; 30(14):S24-S32. PubMed ID: 34288746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
